Monday 01 June 2026
Internal Reference Number: FOI_9379
Date Request Received: 01/05/2026 00:00:00
Date Request Replied To: 18/05/2026 00:00:00
This response was sent via: By Email
Request Summary: Biologics Dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast - Otezla • Apremilast generic • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab - Stelara • Ustekinumab Biosimilar • Omalizumab • Spesolimab | |
| Answer To Question 1: This FOI can answered by viewing the report in the section called "Pharmacy – Number of Patients Treated with Specific Drugs” on the following webpage - https://www.salisbury.nhs.uk/about-us/freedom-of-information-foi/ | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
